PubMed Health⌕ Search

Biomedical subjects

T Mussivand

Publications and source records attributed to T Mussivand.

At least 19 recordsLinked to original sources

HeartSaver VAD: a totally implantable ventricular assist device. Results of in vivo studies.

Currently, the most widely utilized ventricular assist devices (VADs) require percutaneous connections and are located either externally (e.g., Thoratec, Abiomed) or intra-abdominally (e.g., Novacor, TCI). These attributes have been implicated in a variety of complications (infection, thromboembolic, gastrointestinal, etc.). To address these concerns, a totally implantable VAD that requires no percutaneous connections and can be implanted in the left hemi-thorax has been developed. The developed device has undergone in vivo evaluation as part of the design and development process. A total of 43 implants in the bovine model, with 5 device versions, have been conducted between July 1992 and February 2000. These studies successfully have demonstrated several important aspects of the developed device, including 1) feasibility of a totally implantable system; 2) capability of the device to support a dysfunctional heart; and 3) ability of the device to provide flows up to 10 L/min in a physiological setting. The studies to date have played a vital role in the design and development process as well as demonstrating the feasibility of a totally implantable intrathoracic VAD. Based on these studies, design optimization was conducted, resulting in the development of the pre-clinical version of the device in preparation for clinical trials.

Animals↗

Progress with the HeartSaver Ventricular Assist Device.

BACKGROUND: Ventricular assist devices (VADs) have been shown to be effective for short- or long-term circulatory support. Devices are either being adapted or newly designed for longer term or permanent support, with the goal to provide patients with improved quality of life. Since 1990, a program has been in place to develop a totally implantable, permanent VAD. METHODS: A multidisciplinary team is developing this VAD with specific goals in mind: (1) that it have an intrathoracic position, (2) that it be a totally implantable device without any percutaneous connections, and (3) that it be possible to communicate with the device from remote locations. These goals would allow for complete patient mobility and flexibility for follow-up. RESULTS: The electrohydraulically actuated VAD combines the blood pump, volume displacement chamber, energy converter, and internal electronic module into a single compact unit. The device called the HeartSaver VAD is powered by a transcutaneous energy transfer system and can be remotely monitored and controlled. Prototypes of different versions of the device have been tested in vitro and in vivo with satisfactory performance. CONCLUSIONS: The prototypes of the HeartSaver VAD have functioned well under test conditions and fulfilled the outlined goals. Further development and testing of the design are being conducted before clinical availability.

Animals↗

Development of a ventricular assist device for out-of-hospital use.

BACKGROUND: Success with temporary ventricular assist devices, has prompted interest in devices developed for long term use outside of the hospital setting. METHODS: A totally implantable intrathoracic electro-hydraulic ventricular assist device has been developed. Design focused on providing the recipient with a near normal quality of life. To meet this goal the system utilizes transcutaneous energy transfer and biotelemetry to eliminate percutaneous drive-lines/cables as well as a displacement chamber capable of pressure equalization to atmospheric pressures, so as to eliminate the need for percutaneous venting. An implanted battery provides backup power to allow the recipient the ability to bathe, shower, or swim without connection to an external power source. An integrated telemedicine capability allows the device to be monitored/controlled remotely, using telephone lines. RESULTS: The system has been tested in vitro with early prototypes running for up to 5 1/2 years. The system was studied in calves (n = 25) with durations of support of up to 30 days, demonstrating the ability of the device to function as a totally implantable device without percutaneous connections. CONCLUSIONS: The various in vitro and in vivo studies have demonstrated the feasibility of the totally implantable device. Chronic in vivo experiments will follow in preparation for regulatory submissions for human use.

Animals↗

Wireless monitoring and control for implantable rotary blood pumps.

A wireless biotelemetry system for the transfer of digital data through intact skin and tissue has been developed to provide a safe and noninvasive means of communication between implanted medical devices and the outside of the body. The system utilizes 2 miniature infrared transmitter/receiver modules. Data are transmitted through intact skin and subcutaneous tissue on an 890 nm infrared carrier signal. The system has been evaluated in human cadavers and during in vivo implantation of artificial hearts and ventricular assist devices for durations of up to 96 h. Acceptable data transfer (error rate < 10(-5)) through a typical tissue thickness of 5-25 mm has been demonstrated. The ability to monitor and control a device from a remote site using public communication systems such as telephone lines and asynchronous transfer mode (ATM) systems has also been demonstrated. Design optimization is currently ongoing in preparation for clinical utilization with artificial heart systems and other implantable devices (such as rotary blood pumps).

Animals↗

A remotely controlled and powered artificial heart pump.

An intrathoracic pulsatile artificial heart pump has been developed. Transcutaneous energy transfer and biotelemetry systems provide continuous power and remote monitoring and control, with no percutaneous connections required. The electrohydraulic system can be used either as a ventricular assist device or with modifications as a total artificial heart. The device uses a unidirectional axial flow pump coupled with a pressure activated one-way valve to allow hydraulic fluid to passively return to the volume displacement chamber during diastole. The transcutaneous energy transfer system provides power to the device and recharges the implantable battery pack. A wearable external controller and external battery pack provide the patient enhanced mobility and thus an improved quality of life. The biotelemetry system allows control and monitoring of the device after implantation, as well as an added capability to monitor and control the device remotely over public communication lines. Early prototypes have functioned failure free for up to 3 years in vitro. The device has sustained circulation in vivo for up to 4 days. Design optimization is continuing, and chronic in vivo evaluation is planned.

Animals↗

Transcutaneous energy transfer with voltage regulation for rotary blood pumps.

Rotary blood pumps often require a constant operating voltage. To meet this requirement and to eliminate the need for percutaneous leads, a voltage-regulated transcutaneous energy transfer (TET) system has been developed. Voltage regulation is achieved by using a transcutaneous infrared feedback control loop operating on a 890 nanometer (nm) wavelength. In vitro testing of the system developed has shown that output voltage can be maintained to within 0.2 V of nominal (14.5 V) for delivered powers up to 50 watts (W) and coil separations of between 3 and 10 mm. Power transfer efficiencies were determined to be from 68% to 72% over the tested range of coil separations and output currents from 1.5 to 3.6 amperes (A). This system has demonstrated acceptable performance in regulating output voltage while transferring power inductively without using percutaneous connections. By integrating this type of TET system with an implanted rotary blood pump, the quality of life for the device recipient could be improved.

Energy Transfer↗

Assessment of the cytotoxicity of the photosensitizing drug BPD verteporfin using human vascular smooth muscle cells in culture.

Photosensitizing drugs are selectively taken up by lipid-rich lesions such as atheromatous plaque which when exposed to light render the drugs cytotoxic. However, skin photosensitivity which persists for many weeks is a significant side effect. We investigated the cytotoxicity of a new photosensitizing drug, the benzoporphyrin derivative BPD verteporfin (Quadra Logic Technologies), which does not have this deleterious side effect. Vascular smooth muscle cells (VSMC) from normal human mammary and diseased human coronary arteries were grown in culture from explants and characterized with respect to their growth rates. The sensitivity to BPD with and without light was assessed by measuring viability after treatment. The lethal dose of drug for 50% viability loss (LD50) for BPD with light was approximately 12.5 ng/ml for mammary artery, with 52 +/- 8% cell survival (n = 6). The coronary artery VSMC from all patient sources, although differing significantly in growth rate, had a survival of 44 +/- 6% (n = 12) at the same concentration of BPD used for the mammary artery SMC (p = NS). Our results established the LD50 for BPD using human arterial sources of SMC and showed that the growth rates of the cells did not affect the cytotoxicity of the drug.

Cell Survival↗

Comparison of rechargeable lithium and nickel/cadmium battery cells for implantable circulatory support devices.

Size and weight constraints are critical areas in the design of implantable medical devices. For this reason, a study of different rechargeable lithium and nickel/cadmium (Ni/Cd) battery cell types was undertaken to determine which cell type, when assembled into a multicell battery pack, would provide the smallest and lightest power source for implantation. The discharge rate and cycle life characteristics of 2 different rectangular prismatic Ni/Cd cells and 5 different rechargeable lithium cells were determined at 37 degrees C by charge/discharge cycling, the cells using a constant discharge load of 0.87 A. Using the observed discharge rate and cycle life characteristics of the cells, along with the desired performance criteria of 30 min operating time at the end of a 1-year implant period, the projected weight and volume of the various 12-V battery packs were determined. These results showed that one of the rectangular prismatic Ni/Cd cells would yield the smallest (53 ml) and lightest (189 g) 12-V battery pack that met the performance criteria specified. The results also indicate that, for applications requiring long implant times, cycle life can be more important in the selection of cells for a small, lightweight battery pack than specific energy or energy density.

Cadmium↗

Can disturbed brain microcirculation cause Alzheimer's disease?

Recent ultrastructural studies demonstrate characteristic and extensive angio-architectural distortions of cerebral capillaries in Alzheimer's brains. Alzheimer's disease subjects additionally show reduced cerebral blood flow (CBF), glucose metabolism and oxygen utilization which appear inversely proportional to the disease severity. These findings led us to develop a hypothetical model which appears consistent with the pathogenesis and progression of AD. During ageing, brain capillaries (site of the blood-brain barrier) may undergo progressive degeneration caused by amyloid deposits, thickened basement membrane, cerebral atrophy, reduced vessel elasticity, or genetic predisposition. When these structural abnormalities of the brain microvasculature begin to interfere with basic laws of fluid dynamics, haemorheological compromise will result in cerebral capillary resistance, high blood viscosity, abnormal flow patterns, and changes in shear stress and shear rate in vessel walls. The net effect is chronic 'disturbed' blood flow to the brain that impairs the delivery of essential nutrients, particularly oxygen and glucose, to cerebral neurons. As ischaemic-sensitive neurons lower their oxidative phosphorylation and ATP production to subfunctional levels, they release a diffusible glial mitogen that directly stimulates reactive astrocytosis. These reactive glia differ significantly from normal glia because they proliferate mostly in response to brain injury and can spread to unaffected tissue. It has been suggested that amyloid precursor protein (APP) may be expressed from reactive glia following neuronal injury thus providing the nidus of plaque formation. As brain tissue space is invaded by reactive glia and microglia, neuronal cytoskeletal damage can result in neurofibrillary tangles.(ABSTRACT TRUNCATED AT 250 WORDS)

Aging↗

Transcutaneous energy transfer system performance evaluation.

A transcutaneous energy transfer (TET) system has been developed to power implantable devices such as artificial hearts, defibrillators, and electrical stimulators. Transcutaneous coupling of power to these implanted devices remains a favorable alternative as percutaneous lines are avoided in order to eliminate the potential of infection and allow patient mobility. In vitro, in vivo, ex vivo, and human cadaver studies of the electrohydraulic ventricular assist device TET have demonstrated that power can be transmitted over a range of skin thicknesses of 3-15 mm and can tolerate radial misalignments of up to 20 mm. Sensitivity to coil separation and radial misalignment variations has been addressed by the development of an auto-tuning TET. The system has only a 10% attenuation in secondary coil voltage when metallic objects are in contact with the primary coil. The system has demonstrated a power transfer efficiency of 60-80% for power demands from 5 to 70 W. The TET secondary coil will provide an output voltage of 10-25 V for current demands from 0.5 to 4.0 A. TET chronic studies in porcine models have demonstrated no adverse effect to the tissue when up to 40 W of power can be delivered to an implanted load without the tissue-contacting surface of the coil exceeding 42 degrees C. In conclusion, the TET is a feasible alternative for tether-free power transmission.

Cadaver↗

Critical anatomic dimensions for intrathoracic circulatory assist devices.

The design of totally implantable circulatory support devices must account for the anatomical constraints of the body cavity. To aid development of an implantable electrohydraulic ventricular assist device (EVAD), thoracic anatomical measurements and fit trials were performed. Various dimensions of the thoracic cavity were measured in 19 preserved and fresh cadavers. The mean left ventricle apex to chest wall distance was 2.7 +/- 0.2 cm. The mean sagittal radius of curvature at the fifth rib was 11.1 +/- 0.4 cm, and the transverse radius at the fifth rib was 9.4 +/- 0.3 cm. The mean sternal length was 18.9 +/- 1.2 cm. Using these measurements a model measuring 17.5 x 10.5 x 3.8 cm was designed. This model was placed in the chest of 11 patients undergoing open heart surgery. In one patient there was significant lung compression and in another hypotension suggesting great vessel compression. Finally, 1 of 11 patients had a short sternum and a small thorax, and the device did not fit. In conclusion, thoracic measurements may be used in the design of circulatory support devices. The model fit adequately in 73% of patient trials.

Adult↗

Development of compliance chamber diaphragms with reduced permeability.

The implantable ventricular assist systems currently undergoing clinical readiness testing shuttle the displaced gas between the non-blood side of the pumping diaphragm and an elastic chamber generally called a "compliance chamber" or variable volume device. The movement of the stored gas allows the pump to fill and empty without compression or expansion of the gas behind the pump diaphragm. The material used for the construction of compliance chambers should be fatigue resistant to withstand the 63 million flexes per year of the blood pump. The material should also be biocompatible and highly impervious to gases. Significant diffusion of gases from the compliance system necessitates external make-up gases to somehow be added to the internal system. Material selection is complicated by the fact that most fatigue-resistant elastomers also have high gas permeability. In order to solve this problem, bilayer compliance chambers have been developed using biocompatible and fatigue-resistant polyolefin rubber comolded with relatively impervious butyl rubber.

Assisted Circulation↗

In vitro and in vivo performance evaluation of a totally implantable electrohydraulic left ventricular assist system.

The biolized electrohydraulic left ventricle assist devices were tested in 14 calves with an average survival time of 162 days and as long as 250 days without the use of anticoagulants. In vitro, the system pumped 4.1 L/min at a low 4.8 mmHg fill pressure with a mean afterload of 100 mmHg and rate of 46 bpm. A flow rate of 13.5 L/min was observed at 155 bpm and 110 mmHg afterload. Motor frequency and current increased with increasing flow rate (162 Hz, 0.67 amp at 2.5 L/min; 484 Hz, 2.43 amp at 13.5 L/min). Flow rate did not change significantly with afterload pressure. The complete system was implanted in a 100 kg calf. Synchronization of the blood pump with the natural heart was demonstrated at heart rates of 85 to 167 bpm. The synchronized flow rate varied from 6 to 10.5 L/min despite the considerable heart rate changes and stroke variations. The system hemodynamic performances were acceptable and met NIH requirements.

Animals↗

New crisscross-shaped port design for universal serial pumps.

The long range goal is the development of a clinically useful, implantable, skeletal muscle powered cardiac assist device (MCAD). To accomplish this goal, two criteria must be met: good anatomic fit, and antithrombogenicity. Because of the relative locations of the latissimus dorsi (LD) muscle and aorta, there are two possible port arrangements: "crisscrossed" (C design), in which the ports are crossed to anastomotic sites, and "prong" shaped (P design), in which no crossover takes place. The purpose of this paper is to determine which of these designs is best from a fluid dynamic perspective, and hence has the best possibility for low thrombogenicity. Flow visualization (FV) techniques were used during two pumping conditions in a mock loop: worst case (MCAD off) and best case (MCAD driven optimally). Results of the MCAD off tests showed that both designs required immediate actuation (for example, an IABP console). However, FV studies under optimal conditions indicated superiority of the C design, most likely due to kinetic energy-induced rotary motion combined with a minimal interport distance. It is concluded that the C design provides ideal flow dynamics, even in valveless pumps, and also has application to valved devices.

Counterpulsation↗

Electrohydraulic ventricular assist device development.

An electrohydraulic ventricular assist device has been developed. An axial flow pump driven by a brushless DC motor provides actuation. Energy is supplied by internal Ni/Cd batteries and by external Ag/Zn batteries, both rechargeable. Electromagnetic induction is used to pass energy through the skin with a transcutaneous energy transfer (TET) system. Physiologic control, battery management, motor commutation, and communication functions are performed by a surface mount internal controller. An infrared data link within the TET coils provides bidirectional communication between the external and internal controllers. A computer model was developed to predict system performance. The dimensions are 180 mm x 116 mm x 40 mm. An in vitro system pumped 5.7 L/min at 10 mmHg inflow and 100 mmHg outflow pressure. The internal battery can provide the projected energy requirements for 40 min after 540 charge/discharge cycles, and the external battery is capable of 4 hr of operation after 150 cycles. The TET system can deliver 60 W of power and exceeds 80% efficiency between 15 and 30 W. The device configuration is based on human cadaver and intraoperative fit trials. The device is being modified for calf implantation by redirecting the blood ports, increasing the output, and incorporating the internal controller in the unified device base.

Animals↗